SCM
ENGNW icon

Shaolin Capital Management’s enGene Therapeutics Warrants ENGNW Stock Holding History

Shaolin Capital Management’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50,000
Closed -$42.5K – 375
2023
Q4 		$42.5K Buy
+50,000
New +$38.4K ﹤0.01% 225

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Shaolin Capital Management's ENGNW Position: Q1 2024 in Review

Shaolin Capital Management sold out of enGene Therapeutics Warrants (ENGNW) in Q1 2024, closing a stake of 50,000 shares — an estimated $42.5K sold.

Shaolin Capital Management first reported a position in ENGNW in Q4 2023 and held it in 1 quarter. The position peaked at $42.5K in Q4 2023. 16 funds tracked by Wall St. Rank hold ENGNW as of Q1 2024.

  • Shaolin Capital Management reported no remaining enGene Therapeutics Warrants position as of Q1 2024 after selling out during the quarter.
  • Shaolin Capital Management sold 50,000 enGene Therapeutics Warrants shares in Q1 2024, an estimated $42.5K.
  • Shaolin Capital Management first reported a position in enGene Therapeutics Warrants in Q4 2023 and held it in 1 quarter.
  • Shaolin Capital Management's enGene Therapeutics Warrants position peaked at $42.5K in Q4 2023.
  • 16 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2024.

Based on Shaolin Capital Management's 13F filing for Q1 2024, filed 15 May 2024.